Copyright
©2012 Baishideng Publishing Group Co.
World J Gastroenterol. May 14, 2012; 18(18): 2203-2211
Published online May 14, 2012. doi: 10.3748/wjg.v18.i18.2203
Published online May 14, 2012. doi: 10.3748/wjg.v18.i18.2203
Table 2 Characterization of the study population n (%)
CG-casein | IG-soy | Total | P value | |
Demographic characteristics | ||||
Gender | ||||
Male | 49 (61.2) | 53 (66.2) | 102 (63.8) | 0.621 |
Female | 31 (38.8) | 27 (33.8) | 58 (36.2) | |
Marital Status | ||||
Married | 56 (70.0) | 55 (68.7) | 111 (69.4) | 1.001 |
Single, widowed or divorced | 24 (30.0) | 25 (31.3) | 49 (30.6) | |
Anthropometric data | ||||
Body mass index | ||||
< 25 kg/m2 | 40 (50.0) | 43(53.8) | 83 (51.9) | 0.7511 |
≥ 25 kg/m2 | 40 (50.0) | 37(46.2) | 77 (48.1) | |
Waist circumference | ||||
Adequate | 43 (53.7) | 46 (59.0) | 89 (56.3) | 0.5251 |
Inadequate | 37 (46.3) | 32 (41.0) | 69 (43.7) | |
Clinical data | ||||
Genotype | ||||
1 | 66 (88.0) | 61 (79.2) | 127 (83.5) | 0.1891 |
2/3 | 9 (12.0) | 16 (20.8) | 25 (16.5) | |
Necroinflammatory activity | ||||
A0 | 26 (41.3) | 29 (46.8) | 55 (44.0) | 0.7921 |
A1 | 26 (41.3) | 22 (35.5) | 48 (38.4) | |
A2 e A3 | 11 (17.4) | 11 (17.7) | 22 (17.6) | |
Stage of fibrosis | ||||
F0/F1/F2 | 35 (55.6) | 40 (63.5) | 75 (59.5) | 0.4681 |
F3/F4 | 28 (44.4) | 23 (36.5) | 51 (40.5) | |
Hepatic steatosis | ||||
Yes | 24 (40.0) | 19 (29.7) | 43 (34.7) | 0.2601 |
No | 36 (60.0) | 45 (70.3) | 81 (65.3) | |
HOMA-IR | ||||
< 3.0 | 55 (53.9) | 47 (46.1) | 102 (63.7) | 0.251 |
≥ 3.0 | 25 (43.1) | 33 (56.9) | 58 (36.3) | |
Biochemical data | Median (iq r) | Median (iq r) | ||
Glucose (mg/dL) | 91.0 (14.2) | 91.5 (14.2) | 0.702 | |
HOMA-IR | 2.35 (2.24) | 2.26 (2.59) | 0.992 | |
Triglycerides (mg/dL) | 96.5 (60.2) | 96.0 (67.2) | 0.572 | |
Total cholesterol (mg/dL) | 149.0 (49.7) | 160.0 (44.0) | 0.422 | |
HDL (mg/dL) | 44.0 (14.2) | 44.0 (15.5) | 0.302 | |
LDL (mg/dL) | 90.5 (40.7) | 90.0 (43.0) | 0.942 | |
AST (U/L) | 59.5 (40.7) | 52.0 (44.5) | 0.142 | |
ALT (U/L) | 76.5 (54.5) | 73.5 (53.0) | 0.382 | |
γGT (U/L) | 102.0 (118.0) | 87.0 (114.0) | 0.712 | |
Alkaline phosphatase (U/L) | 79.0 (33.5) | 80.0 (53.2) | 0.492 |
- Citation: Oliveira LP, Jesus RP, Boulhosa RS, Mendes CMC, Gnoatto MC, Lemaire DC, Toralles MBP, Cavalcante LN, Lyra AC, Lyra LG. Effect of soy protein supplementation in patients with chronic hepatitis C: A randomized clinical trial. World J Gastroenterol 2012; 18(18): 2203-2211
- URL: https://www.wjgnet.com/1007-9327/full/v18/i18/2203.htm
- DOI: https://dx.doi.org/10.3748/wjg.v18.i18.2203